Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 25, 2025 14:30 ET | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; February 25, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,058 shares as a consequence of the exercise of employee warrants. The...
February 20, 2025 08:00 ET | Source: Genmab A/S

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

Media ReleaseCOPENHAGEN, Denmark; February 20, 2025 Approval based on results from two Phase 1/2 EPCORE® clinical trials, which demonstrated strong and durable efficacy in patients with relapsed or...
February 19, 2025 09:14 ET | Source: Genmab A/S

Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference

Media ReleaseCOPENHAGEN, Denmark; February 19, 2025Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano and Chief Development Officer Judith Klimovsky will...
February 13, 2025 06:00 ET | Source: Genmab A/S

Notice to Convene the Annual General Meeting of Genmab A/S

Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 12, 2025 COPENHAGEN, Denmark; February 13, 2025 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on...
February 12, 2025 13:14 ET | Source: Genmab A/S

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

Media ReleaseCOPENHAGEN, Denmark; February 12, 2025 Genmab filed Form 20-F for the financial year 2024 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report...
February 12, 2025 11:01 ET | Source: Genmab A/S

Genmab Publishes 2024 Annual Report

Company Announcement COPENHAGEN, Denmark; February 12, 2025 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024,...
January 23, 2025 15:08 ET | Source: Genmab A/S

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; January 23, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 4,903 restricted stock units and 5,289 warrants to employees of...
January 22, 2025 06:23 ET | Source: Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

Company Announcement Net sales of DARZALEX® in 2024 totaled USD 11,670 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.)...
January 03, 2025 13:56 ET | Source: Genmab A/S

Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Media ReleaseCOPENHAGEN, Denmark; January 03, 2025Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 43rd Annual J.P. Morgan...
December 11, 2024 08:20 ET | Source: Genmab A/S

Genmab to Hold 2024 R&D Update and ASH Data Review Meeting

Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 11, 2024 – Genmab A/S (Nasdaq: GMAB) will hold its 2024 R&D Update and ASH...